| Name | AS-35 |
| Description | AS-35 is an orally effective, potent, and selective antagonist of leukotrienes, antagonizing LTC4-, LTD4-, and LTE4-induced ileum contractions with IC50 values of 8 nM, 4 nM, and 3 nM, respectively. It exhibits antiallergic activities. |
| In vitro | In the trachea, the drug also antagonized LTD4- and LTE4-induced contraction with IC50 values of 10 nM and 20 nM, respectively. In isolated guinea pig preparations, AS-35 antagonized LTC4, LTD4, and LTE4-induced ileal contractions with IC50 values of 8 nM, 4 nM, and 3 nM, respectively. AS-35 does not antagonize LTC4-induced tracheal constriction in the presence of L-serine borate [1]. |
| In vivo | AS-35 (p.o.) inhibits LTD4-induced increase in vascular permeability in guinea pig skin [1]. Oral administration of AS-35 also antagonized LTD4 as well as antigen-induced LT-mediated bronchoconstriction. AS-35 (0.0375 to 0.3 mg/kg, i.v.) dose-dependently antagonized bronchoconstriction induced by intravenous administration of LTC4 and LTD4 but not histamine-induced bronchoconstriction in anesthetized guinea pigs.[1] |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | LTE4 | LTD4 | LTC4 | LeukotrieneReceptor | Leukotriene Receptor | AS-35 | AS35 | AS 35 |
| Inhibitors Related | Moxilubant HCl | Montelukast sodium | LTB4-IN-1 | L 674573 | Olsalazine disodium | Pirodomast | Pranlukast | Desloratadine | CGP 35949 | ABT-080 | Darbufelone mesylate | Ticolubant |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
